
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc has demonstrated a robust commitment to increasing its advertising spend, which rose by 34% year-over-year to $100 million in 2023, leading to improved awareness and procedural growth in obstructive sleep apnea treatments. The company has also reiterated its revenue guidance for 2025, supported by a notable increase in earnings per share (EPS) following a strong third-quarter performance, which saw EPS projections raised by $0.50. Furthermore, expectations for increased average selling prices (ASPs) in 2026, paired with improved reimbursement prospects, suggest a favorable outlook for revenue growth and market penetration moving forward.
Bears say
Inspire Medical Systems has faced a decline in advertising expenses, with 2024 ad spend projected at $95 million, reflecting a year-over-year decrease of 5%. Management has revised its revenue and EPS outlook downward due to challenges associated with the launch of its new product, Inspire 5, resulting in expectations for slower adoption and growth. Additionally, a notable reduction in operating expenses, particularly in research and development, highlights a cautious approach that may hinder long-term revenue growth, further contributing to a negative sentiment on the company's stock.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares